Related Experiment Video
Updated: Jan 20, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Potential Fluid Biomarkers for the Diagnosis of Mild Cognitive Impairment
Vo Van Giau1, Eva Bagyinszky2, Seong Soo A An3
1Department of BionanoTechnology, Gachon University, 1342 Sungnam Daero, Sungnamsi 13120, Korea.
Abstract:
Mild cognitive impairment (MCI) is characterized by a level of cognitive impairment that is lower than normal for a person's age, but a higher function than that that observed in a demented person. MCI represents a transitional state between normal aging and dementia disorders, especially Alzheimer's disease (AD). Much effort has been made towards determining the prognosis of a person with MCI who will convert to AD. It is now clear that cerebrospinal fluid (CSF) levels of Aβ40, Aβ42, total tau and phosphorylated tau are useful for predicting the risk of progression from MCI to AD. This review highlights the advantages of the current blood-based biomarkers in MCI, and discusses some of these challenges, with an emphasis on recent studies to provide an overview of the current state of MCI.
Insights
Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia. This review focuses on blood-based biomarkers for predicting Alzheimer's disease progression from MCI.
Area of Science:
- Neurology
- Biochemistry
- Gerontology
Background:
- Mild cognitive impairment (MCI) signifies a cognitive decline below normal aging but above dementia levels.
- MCI is a critical transitional phase, particularly concerning progression to Alzheimer's disease (AD).
Purpose of the Study:
- To review the advantages and challenges of current blood-based biomarkers for MCI.
- To provide an overview of recent studies on MCI biomarkers and their role in predicting AD conversion.
Main Methods:
- Review of recent scientific literature focusing on cerebrospinal fluid (CSF) and blood-based biomarkers.
- Analysis of studies examining Aβ40, Aβ42, total tau, and phosphorylated tau levels.
Main Results:
- Cerebrospinal fluid (CSF) biomarkers like Aβ40, Aβ42, total tau, and phosphorylated tau are established predictors of MCI to AD progression.
- Emerging blood-based biomarkers show promise but face challenges in widespread clinical application.
Conclusions:
- Blood-based biomarkers offer a less invasive alternative to CSF analysis for assessing MCI and predicting AD risk.
- Continued research is crucial to overcome challenges and validate blood biomarkers for routine clinical use in managing MCI.
More Related Videos
Related Concept Videos
Cognitive Dissonance
Standard Electrode Potentials
Nursing Diagnosis
The nursing diagnosis focuses on evidence-based...
The Fluid Mosaic Model
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
Documentation of Nursing Diagnosis
In some settings, data-driven computerized decision support systems are in place, allowing for more accurate nursing diagnoses. The database within one of these systems includes diagnostic labels defining characteristics, activities, and indicators for nursing. A nurse enters...

